Addition of ISIS 14803 to therapy with peginterferon and ribavirin for chronic hepatitis C (HCV) patients not responding adequately to the two drugs
Phase of Trial: Phase I/II
Latest Information Update: 25 Jan 2016
At a glance
- Drugs ISIS 14803 (Primary) ; Peginterferon alfa; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Ionis Pharmaceuticals
- 16 Oct 2007 Status changed from in progress to completed.
- 22 Oct 2005 New trial record.